VoqX detects infrasound and audible sounds to identify clinical conditions. Credit: Uri Meirovitch / Tiko Product Design Studio / Sanolla / PRNewswire.

The US Food and Drug Administration (FDA) has granted 510(k) clearance for the clinical use of Sanolla’s AI-ready VoqX infrasound stethoscope.

VoqX detects infrasound and audible sounds to identify clinical conditions, displaying diagnosis through the company’s sound signature image.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

It is claimed to be the world’s first stethoscope that can listen to infrasound or acoustic waves that humans cannot hear.

Recently, the device received regulatory approval from the Israeli Health Ministry.

With the approvals, the company will make the new infrasound stethoscope available for clinical use in Israel and the US immediately.

See Also:

Sanolla aims to replace all existing archaic-technology stethoscopes with its new smart infrasound stethoscope.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The new technology, named ‘The Sounds of Life’, picks up low-frequency sound waves (3Hz-40Hz), also known as infrasound, which cannot be heard by human ears.

The smart signal processing technology of the device transfers sounds to the most sensitive frequency range of the ear.

Sanolla co-founder and CEO Dr Doron Adler said: “FDA clearance is an important milestone for Sanolla.

“The VoqX, which has been used extensively for studies in the United States, Europe and Israel, is now available for clinical use.

“Our distribution partners have been waiting for this moment to begin sales in the US and other territories.”

The company has also developed the PyXy home monitoring device for managing chronic illness and early exacerbation detection for chronic cardiopulmonary diseases.

Sanolla’s artificial intelligence (AI) algorithms provide unmatched disease classification of several cardiopulmonary diseases, such as chronic obstructive pulmonary disease (COPD), asthma, pneumonia and cardiac morbidities.

Established in 2016, Sanolla has raised $16m to date and is set to commence Round A funding to cover marketing, sales, R&D, manufacturing partnerships and regulatory approvals.